Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide
作者： Mao-tao Huang , Zhi-xin Chen , Bing Wei , Bo Zhang , Chun-hui Wang
DOI: 10.1111/J.1745-7254.2007.00652.X
关键词: Necrosis 、 Medicine 、 Celecoxib 、 Cyclooxygenase 、 Octreotide 、 TUNEL assay 、 Internal medicine 、 Somatostatin receptor 、 Gastroenterology 、 Endocrinology 、 Growth inhibition 、 Apoptosis
摘要: Aim: To gain insight into the histopathological responses and molecular targets in inhibition of growth human gastric cancer treated with celecoxib (a cyclooxygenase [COX]-2 inhibitor) combined octreotide. Methods: Seventy five patients undergoing curative gastrectomy or extended resection were randomly divided 3 groups. The apoptosis tumor cells was measured by terminal deoxynucleotide transferase-mediated dUTP nick end-labeling (TUNEL) assay. Gastric microvessel density (MVD) expression COX-2 evaluated immunohistochemical staining. somatostatin receptor (SSTR)-2 detected biomolecular interaction analysis system. transcription non-steroidal anti-inflammatory drug-activated gene (NAG)-1 RT-PCR. Results: Compared control groups, more necrosis combination group observed. apoptotic rate (7.06%±0.67%) significantly higher than that (6.23%±1.29%, P Conclusion: Celecoxib octreotide promoted adenocarci-noma through induction reduction MVD. NAG-1 SSTR-2 might be for octreotide.
chinaphar.com
nature.com参考文章(27)
Robert B Diasio, Jeanne Fourie, Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs. ,vol. 66, pp. 1441- 1463 ,(2006) , 10.2165/00003495-200666110-00003
Chun-Hui Wang, Inhibitory effect of octreotide on gastric cancer growthviaMAPK pathway World Journal of Gastroenterology. ,vol. 9, pp. 1904- 1908 ,(2003) , 10.3748/WJG.V9.I9.1904
C C Chan, I W Rodger, Y Girard, D Riendeau, J P Falgueyret, C Brideau, D Ethier, M Gresser, R W Friesen, E Wong, S Boyce, M D Percival, D Dubé, P Prasit, D Visco, A W Ford-Hutchinson, J Mancini, S Charleson, G Greig, J Guay, R Zamboni, M Ouellet, L Xu, R N Young, R Gordon, Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2 Journal of Pharmacology and Experimental Therapeutics. ,vol. 296, pp. 558- 566 ,(2001)
Heather Lindsey, Preoperative chemoradiotherapy shows promise in gastric cancer. Lancet Oncology. ,vol. 5, pp. 519- 519 ,(2004) , 10.1016/S1470-2045(04)01550-5
Kazuhiko Uefuji, Takashi Ichikura, Hidetaka Mochizuki, Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. Journal of Surgical Oncology. ,vol. 76, pp. 26- 30 ,(2001) , 10.1002/1096-9098(200101)76:1<26::AID-JSO1005>3.0.CO;2-A
Keun -Sang Kwon, Han -Jung Chae, Sodium salicylate inhibits expression of COX-2 through suppression of ERK and subsequent NF-κB activation in Rat ventricular cardiomyocytes Archives of Pharmacal Research. ,vol. 26, pp. 545- 553 ,(2003) , 10.1007/BF02976879
Seung Joon Baek, Jong-Sik Kim, Scott M. Moore, Seong-Ho Lee, Jeanelle Martinez, Thomas E. Eling, Cyclooxygenase Inhibitors Induce the Expression of the Tumor Suppressor Gene EGR-1, Which Results in the Up-Regulation of NAG-1, an Antitumorigenic Protein Molecular Pharmacology. ,vol. 67, pp. 356- 364 ,(2005) , 10.1124/MOL.104.005108
Ryo Ohno, Keigo Yoshinaga, Takeshi Fujita, Kumi Hasegawa, Hideaki Iseki, Hidefumi Tsunozaki, Wataru Ichikawa, Zenro Nihei, Kenichi Sugihara, Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer. ,vol. 91, pp. 1876- 1881 ,(2001) , 10.1002/1097-0142(20010515)91:10<1876::AID-CNCR1209>3.0.CO;2-H
Elias A. Kouroumalis, Octreotide for Cancer of the Liver and Biliary Tree Chemotherapy. ,vol. 47, pp. 150- 161 ,(2001) , 10.1159/000049167
M. N. Pollak, A. V. Schally, Mechanisms of Antineoplastic Action of Somatostatin Analogs Experimental Biology and Medicine. ,vol. 217, pp. 143- 152 ,(1998) , 10.3181/00379727-217-44216